Pfizer The EMA investigates the need to inoculate a third dose six months after the second
The
Public Health Commission
has approved this Tuesday to administer an additional dose of the vaccine against
Covid-19
to people in a situation of
severe immunosuppression
, in whom there is a high risk of an inadequate immune response to the conventional vaccination schedule. .
Specifically, the additional dose to complete the vaccination regimen is indicated for people with solid organ transplants, hematopoietic stem cell transplant recipients, and people receiving anti-CD20 drugs.
The inoculation of said dose should be carried out
at least 28 days after receiving the previous dose
.
In the case of people undergoing treatment with anti-CD20 drugs -including rituximaba or veltuzumab, among others-, it must be administered
six months
after the end of therapy.
The body determines that in all these cases
mRNA vaccine will be administered
, preferably the same type of vaccine as the one previously administered.
It also recommends continuing to review the evidence of the benefits that an additional dose can bring in other immunosuppressive situations, such as oncohematological patients undergoing chemo-radiotherapy treatment and in those with underlying pathologies that require immunosuppressive treatment.
The
Public Health Commission
has indicated that at the present time there are no solid data to support the administration of a booster dose to the rest of the population.
According to the criteria of The Trust Project
Know more
Vaccines
Covid 19
Babies transmit more Covid than adolescents indoors
Turkey authorizes the fourth dose for those immunized with the Chinese Sinovac vaccine
SaludCanarias advances to 2 months the vaccination of those who have passed the Covid
See links of interest
Last News
Work calendar
Home THE WORLD TODAY
Master Investigation Journalism
The last temptation
Huesca - Real Oviedo